pd-1抗体sintilimab联合pegaspargase和anlotinib治疗iv期NKTCL患者的疗效和安全性的多中心前瞻性研究

IF 3.3 4区 医学 Q2 HEMATOLOGY
R. Tao, C. Liu, W. Zhang, J. Wan, Y. Ma, Y. Zhu, L. Ma, S. Tian, H. Ding
{"title":"pd-1抗体sintilimab联合pegaspargase和anlotinib治疗iv期NKTCL患者的疗效和安全性的多中心前瞻性研究","authors":"R. Tao,&nbsp;C. Liu,&nbsp;W. Zhang,&nbsp;J. Wan,&nbsp;Y. Ma,&nbsp;Y. Zhu,&nbsp;L. Ma,&nbsp;S. Tian,&nbsp;H. Ding","doi":"10.1002/hon.70094_400","DOIUrl":null,"url":null,"abstract":"<p><b>Introduction:</b> Stage IV Natural killer/T-cell lymphoma (NKTCL) has a poor prognosis. Asparaginase is the backbone drug for the treatment of NKTCL. Anti-PD-1 antibody is effective for relapsed/refractory NKTCL. Our previous study found that angiogenesis inhibitor anlotinib was active in relapsed/refractory NKTCL. This study is aimed to investigate the efficacy and safety of Sintilimab, a PD-1 antibody approved in China, in combination with Pegaspargase and anlotinib (LEAP regimen) in the treatment of stage IV NKTCL patients unfit for high-dose induction chemotherapy.</p><p><b>Methods:</b> Eligible patients met the following criteria: (1) Histologically confirmed NKTCL with stage IV classification per Lugano 2014 criteria; (2) Age &gt; 65 years or ≤ 65 years with protocol-defined contraindications to high-dose methotrexate/dexamethasone. The LEAP regimen comprised 3-week cycles (maximum 8 cycles): Sintilimab 200 mg IV day 1; Pegaspargase 2500 IU/m<sup>2</sup> IM day 1; Anlotinib 8 mg PO days 1–14. Complete responders could receive consolidative autologous hematopoietic stem cell transplantation (auto-HSCT) at investigator discretion. The primary endpoint was complete response (CR) rate at 24 weeks by Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety analysis using CTCAE v4.0.</p><p><b>Results:</b> Thirty-seven patients were enrolled (median age 64 years; range 32–78; M:F = 22:15) from July 2019 to April 2021. The median treatment duration was 8 cycles (range 2–8), with 72.9% (27/37) achieving CR and an objective response rate of 83.8% (31/37). Disease progression occurred in 16.2% (6/37) during treatment. Following induction therapy, 63.0% (17/27) of CR patients underwent consolidative auto-HSCT versus 37.0% (10/27) who entered observation. With a median follow-up of 48 months (95% CI: 45.2–50.8), the auto-HSCT cohort demonstrated significantly lower relapse rates (17.6% vs. 60.0%, <i>p</i> &lt; 0.05). Survival outcomes revealed 1-/4-year PFS rates of 78.4% (95% CI: 61.4%–88.6%)/56.6% (39.2%–70.7%) and 1-/4-year OS rates of 83.8% (67.4%–92.4%)/75.2% (57.7%–86.3%). All patients experienced treatment-related adverse events (AEs), predominantly grade 1–2 asparaginase-associated toxicities). Grade ≥ 3 AEs included neutropenia (10.8%) and hyperbilirubinemia (10.8%). No AE-related treatment discontinuations occurred.</p><p><b>Conclusions:</b> The LEAP regimen demonstrates robust clinical efficacy (CR rate 72.9%) and favorable tolerability in high-risk stage IV NKTCL patients ineligible for intensive induction chemotherapy. However, the high post-remission relapse rate (60%) in non-consolidated patients underscores the necessity for effective maintenance strategies. Our findings suggest consolidative auto-HSCT significantly improves disease free survival, potentially bridging the gap between immunotherapy and durable remission in this challenging patient population.</p><p><b>Keywords:</b> aggressive T-cell non-Hodgkin lymphoma; combination therapies; immunotherapy</p><p>No potential sources of conflict of interest.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_400","citationCount":"0","resultStr":"{\"title\":\"A MULTI-CENTER, PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF PD-1 ANTIBODY SINTILIMAB IN COMBINATION WITH PEGASPARGASE AND ANLOTINIB IN STAGE IV NKTCL PATIENTS\",\"authors\":\"R. Tao,&nbsp;C. Liu,&nbsp;W. Zhang,&nbsp;J. Wan,&nbsp;Y. Ma,&nbsp;Y. Zhu,&nbsp;L. Ma,&nbsp;S. Tian,&nbsp;H. Ding\",\"doi\":\"10.1002/hon.70094_400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Introduction:</b> Stage IV Natural killer/T-cell lymphoma (NKTCL) has a poor prognosis. Asparaginase is the backbone drug for the treatment of NKTCL. Anti-PD-1 antibody is effective for relapsed/refractory NKTCL. Our previous study found that angiogenesis inhibitor anlotinib was active in relapsed/refractory NKTCL. This study is aimed to investigate the efficacy and safety of Sintilimab, a PD-1 antibody approved in China, in combination with Pegaspargase and anlotinib (LEAP regimen) in the treatment of stage IV NKTCL patients unfit for high-dose induction chemotherapy.</p><p><b>Methods:</b> Eligible patients met the following criteria: (1) Histologically confirmed NKTCL with stage IV classification per Lugano 2014 criteria; (2) Age &gt; 65 years or ≤ 65 years with protocol-defined contraindications to high-dose methotrexate/dexamethasone. The LEAP regimen comprised 3-week cycles (maximum 8 cycles): Sintilimab 200 mg IV day 1; Pegaspargase 2500 IU/m<sup>2</sup> IM day 1; Anlotinib 8 mg PO days 1–14. Complete responders could receive consolidative autologous hematopoietic stem cell transplantation (auto-HSCT) at investigator discretion. The primary endpoint was complete response (CR) rate at 24 weeks by Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety analysis using CTCAE v4.0.</p><p><b>Results:</b> Thirty-seven patients were enrolled (median age 64 years; range 32–78; M:F = 22:15) from July 2019 to April 2021. The median treatment duration was 8 cycles (range 2–8), with 72.9% (27/37) achieving CR and an objective response rate of 83.8% (31/37). Disease progression occurred in 16.2% (6/37) during treatment. Following induction therapy, 63.0% (17/27) of CR patients underwent consolidative auto-HSCT versus 37.0% (10/27) who entered observation. With a median follow-up of 48 months (95% CI: 45.2–50.8), the auto-HSCT cohort demonstrated significantly lower relapse rates (17.6% vs. 60.0%, <i>p</i> &lt; 0.05). Survival outcomes revealed 1-/4-year PFS rates of 78.4% (95% CI: 61.4%–88.6%)/56.6% (39.2%–70.7%) and 1-/4-year OS rates of 83.8% (67.4%–92.4%)/75.2% (57.7%–86.3%). All patients experienced treatment-related adverse events (AEs), predominantly grade 1–2 asparaginase-associated toxicities). Grade ≥ 3 AEs included neutropenia (10.8%) and hyperbilirubinemia (10.8%). No AE-related treatment discontinuations occurred.</p><p><b>Conclusions:</b> The LEAP regimen demonstrates robust clinical efficacy (CR rate 72.9%) and favorable tolerability in high-risk stage IV NKTCL patients ineligible for intensive induction chemotherapy. However, the high post-remission relapse rate (60%) in non-consolidated patients underscores the necessity for effective maintenance strategies. Our findings suggest consolidative auto-HSCT significantly improves disease free survival, potentially bridging the gap between immunotherapy and durable remission in this challenging patient population.</p><p><b>Keywords:</b> aggressive T-cell non-Hodgkin lymphoma; combination therapies; immunotherapy</p><p>No potential sources of conflict of interest.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 S3\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_400\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_400\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_400","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

IV期自然杀伤/ t细胞淋巴瘤(NKTCL)预后较差。天冬酰胺酶是治疗NKTCL的骨干药物。抗pd -1抗体对复发/难治性NKTCL有效。我们之前的研究发现血管生成抑制剂anlotinib在复发/难治性NKTCL中有活性。本研究旨在探讨中国已获批的PD-1抗体Sintilimab联合Pegaspargase和anlotinib (LEAP方案)治疗不适合大剂量诱导化疗的ⅳ期NKTCL患者的疗效和安全性。方法:符合以下标准的患者:(1)根据Lugano 2014标准,组织学证实为NKTCL,分期为IV期;(2)年龄;65岁或≤65岁,有方案规定的大剂量甲氨蝶呤/地塞米松禁忌症。LEAP方案包括3周周期(最多8个周期):辛替单抗200mg IV第1天;Pegaspargase 2500 IU/m2 IM第1天;安洛替尼8mg PO天1-14。完全应答者可以接受巩固性自体造血干细胞移植(auto-HSCT)。根据Lugano 2014标准,主要终点是24周的完全缓解(CR)率。次要终点包括无进展生存期(PFS)、总生存期(OS)和使用CTCAE v4.0进行的安全性分析。结果:37例患者入组(中位年龄64岁;32 - 78;M:F = 22:15)从2019年7月到2021年4月。中位治疗持续时间为8个周期(范围2-8),72.9%(27/37)达到CR,客观缓解率为83.8%(31/37)。16.2%(6/37)的患者在治疗期间出现疾病进展。诱导治疗后,63.0%(17/27)的CR患者接受了巩固性自体造血干细胞移植,而进入观察期的患者为37.0%(10/27)。中位随访时间为48个月(95% CI: 45.2-50.8), auto-HSCT队列显示复发率显著降低(17.6% vs. 60.0%, p <;0.05)。生存结果显示1- 4年PFS率为78.4% (95% CI: 61.4%-88.6%)/56.6%(39.2%-70.7%), 1- 4年OS率为83.8%(67.4%-92.4%)/75.2%(57.7%-86.3%)。所有患者均出现治疗相关不良事件(ae),主要是1-2级天冬酰胺酶相关毒性。≥3级ae包括中性粒细胞减少症(10.8%)和高胆红素血症(10.8%)。没有发生与ae相关的治疗中断。结论:LEAP方案在不适合强化诱导化疗的高危IV期NKTCL患者中具有良好的临床疗效(CR率为72.9%)和耐受性。然而,非巩固患者的高缓解后复发率(60%)强调了有效维持策略的必要性。我们的研究结果表明,在这一具有挑战性的患者群体中,巩固性自体造血干细胞移植显着提高了无病生存率,可能弥合了免疫治疗和持久缓解之间的差距。关键词:侵袭性t细胞非霍奇金淋巴瘤;联合疗法;没有潜在的利益冲突来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A MULTI-CENTER, PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF PD-1 ANTIBODY SINTILIMAB IN COMBINATION WITH PEGASPARGASE AND ANLOTINIB IN STAGE IV NKTCL PATIENTS

Introduction: Stage IV Natural killer/T-cell lymphoma (NKTCL) has a poor prognosis. Asparaginase is the backbone drug for the treatment of NKTCL. Anti-PD-1 antibody is effective for relapsed/refractory NKTCL. Our previous study found that angiogenesis inhibitor anlotinib was active in relapsed/refractory NKTCL. This study is aimed to investigate the efficacy and safety of Sintilimab, a PD-1 antibody approved in China, in combination with Pegaspargase and anlotinib (LEAP regimen) in the treatment of stage IV NKTCL patients unfit for high-dose induction chemotherapy.

Methods: Eligible patients met the following criteria: (1) Histologically confirmed NKTCL with stage IV classification per Lugano 2014 criteria; (2) Age > 65 years or ≤ 65 years with protocol-defined contraindications to high-dose methotrexate/dexamethasone. The LEAP regimen comprised 3-week cycles (maximum 8 cycles): Sintilimab 200 mg IV day 1; Pegaspargase 2500 IU/m2 IM day 1; Anlotinib 8 mg PO days 1–14. Complete responders could receive consolidative autologous hematopoietic stem cell transplantation (auto-HSCT) at investigator discretion. The primary endpoint was complete response (CR) rate at 24 weeks by Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety analysis using CTCAE v4.0.

Results: Thirty-seven patients were enrolled (median age 64 years; range 32–78; M:F = 22:15) from July 2019 to April 2021. The median treatment duration was 8 cycles (range 2–8), with 72.9% (27/37) achieving CR and an objective response rate of 83.8% (31/37). Disease progression occurred in 16.2% (6/37) during treatment. Following induction therapy, 63.0% (17/27) of CR patients underwent consolidative auto-HSCT versus 37.0% (10/27) who entered observation. With a median follow-up of 48 months (95% CI: 45.2–50.8), the auto-HSCT cohort demonstrated significantly lower relapse rates (17.6% vs. 60.0%, p < 0.05). Survival outcomes revealed 1-/4-year PFS rates of 78.4% (95% CI: 61.4%–88.6%)/56.6% (39.2%–70.7%) and 1-/4-year OS rates of 83.8% (67.4%–92.4%)/75.2% (57.7%–86.3%). All patients experienced treatment-related adverse events (AEs), predominantly grade 1–2 asparaginase-associated toxicities). Grade ≥ 3 AEs included neutropenia (10.8%) and hyperbilirubinemia (10.8%). No AE-related treatment discontinuations occurred.

Conclusions: The LEAP regimen demonstrates robust clinical efficacy (CR rate 72.9%) and favorable tolerability in high-risk stage IV NKTCL patients ineligible for intensive induction chemotherapy. However, the high post-remission relapse rate (60%) in non-consolidated patients underscores the necessity for effective maintenance strategies. Our findings suggest consolidative auto-HSCT significantly improves disease free survival, potentially bridging the gap between immunotherapy and durable remission in this challenging patient population.

Keywords: aggressive T-cell non-Hodgkin lymphoma; combination therapies; immunotherapy

No potential sources of conflict of interest.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信